The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age

Front Immunol. 2022 Dec 15:13:1094727. doi: 10.3389/fimmu.2022.1094727. eCollection 2022.

Abstract

SARS-CoV-2 mRNA vaccines prevent severe COVID-19 by generating immune memory, comprising specific antibodies and memory B and T cells. Although children are at low risk of severe COVID-19, the spreading of highly transmissible variants has led to increasing in COVID-19 cases and hospitalizations also in the youngest, but vaccine coverage remains low. Immunogenicity to mRNA vaccines has not been extensively studied in children 5 to 11 years old. In particular, cellular immunity to the wild-type strain (Wuhan) and the cross-reactive response to the Omicron variant of concern has not been investigated. We assessed the humoral and cellular immune response to the SARS-CoV-2 BNT162b2 vaccine in 27 healthy children. We demonstrated that vaccination induced a potent humoral and cellular immune response in all vaccinees. By using spike-specific memory B cells as a measurable imprint of a previous infection, we found that 50% of the children had signs of a past, undiagnosed infection before vaccination. Children with pre-existent immune memory generated significantly increased levels of specific antibodies, and memory T and B cells, directed against not only the wild type virus but also the omicron variant.

Keywords: Omicron; SARS-CoV-2; antibodies; antigen-specific T cells; children; immune memory; memory B cells; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies
  • BNT162 Vaccine
  • COVID-19* / prevention & control
  • Child
  • Child, Preschool
  • Humans
  • Immunologic Memory
  • SARS-CoV-2
  • Vaccines*
  • mRNA Vaccines

Substances

  • BNT162 Vaccine
  • Vaccines
  • mRNA Vaccines
  • Antibodies

Supplementary concepts

  • SARS-CoV-2 variants